The withdrawal of the UK from the European Union (EU) is a complicated event. Although implications vary by industry, the biotechnology sector is especially vulnerable to the consequences of Brexit. Accordingly, here we evaluate potential repercussions under four post-Brexit political pathways: European Economic Area (EEA) affiliation (Norwegian Model); negotiated bilateral access (Swiss Model); limited participation in EU Customs Union (Turkish Model); or independence under the World Trade Organization (WTO) designation. We conclude that all four pathways fail to protect the mutually beneficial UK–EU biotechnology relationship and that alternative pathways need to be explored. Accordingly, we outline a suite of policy mechanisms aimed at ensuring continued EU–UK regulatory synergy, with the central aim of ensuring access to biomedical innovations and ensuring patient safety.

英国从欧洲联盟（EU）撤军是一个复杂的事件。尽管影响因行业而异，但生物技术行业尤其容易受到英国退欧的影响。因此，在这里，我们评估了英国脱欧后四种政治路径下的潜在影响：欧洲经济区（EEA）隶属关系（挪威模式）；谈判双边准入（瑞士模式）；有限参与欧盟关税同盟（土耳其模式）；或根据世界贸易组织（WTO）的名称获得独立。我们得出的结论是，所有四种途径都无法保护英国与欧盟之间互惠互利的生物技术关系，因此需要探索其他途径。因此，我们概述了一套旨在确保欧盟与英国之间持续的监管协同作用的政策机制，